SPARC collaborates with Schrodinger for drug development

Sun Pharma Advanced Research Company (SPARC) announced a research collaboration with Schrodinger by means of which the two entities aim to accelerate the Neurodegeneration Drug Development Program.

The initiative will propel discovery of novel CNS therapeutics by capitalizing on Schrodinger’s advanced computational platform and SPARC’s wide-ranging drug development proficiency and insights in neurodegeneration.

Schrodinger is a privately held company which employs advanced molecular simulation for drug discovery. The company focuses on lead discovery and optimization. On the other hand, SPARC, which is primarily engaged in bettering patient care through innovation, is responsible for compound synthesis and assays. Thus, the collaboration is symbiotic in the sense that SPARC’s association with academic researchers to explore pathways targeting disorders of the central nervous system will assist Schrodinger in drug development in the area of Neurodegeneration.

On Monday, the shares of SPARC opened at Rs.258.05 per share and hit a high and low of Rs. 258.05 per share and Rs. 245.65 per share, respectively. At 10:06 am, the stock was trading at Rs. 251.50 per share, down 3.25 per cent.